China 2014 Regulatory Outlook: Expect Greater Enforcement As CFDA Rolls Out New Regs
This article was originally published in The Pink Sheet Daily
The year 2014 could see China FDA implement a series of rules, including revisions to the Drug Registration Regulation and the Medical Device Administration Regulation, which could significantly impact the pharmaceutical and medical device industries.
You may also be interested in...
The agency is waiting for approval to locate 10 new drug inspectors in China.
U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.